Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
By EsqSocial Corporation 10/05/21
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital. Capsida secured a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners, and a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addition to potential future option, development, and commercial milestone payments....
By: Rothwell, Figg, Ernst & Manbeck, P.C.